Jakub Radocha

1.1k total citations
57 papers, 287 citations indexed

About

Jakub Radocha is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Jakub Radocha has authored 57 papers receiving a total of 287 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Hematology, 26 papers in Molecular Biology and 25 papers in Oncology. Recurrent topics in Jakub Radocha's work include Multiple Myeloma Research and Treatments (32 papers), Protein Degradation and Inhibitors (13 papers) and Cancer Treatment and Pharmacology (10 papers). Jakub Radocha is often cited by papers focused on Multiple Myeloma Research and Treatments (32 papers), Protein Degradation and Inhibitors (13 papers) and Cancer Treatment and Pharmacology (10 papers). Jakub Radocha collaborates with scholars based in Czechia, Germany and Slovakia. Jakub Radocha's co-authors include Katja Weisel, Niels W.C.J. van de Donk, Vladimír Maisnar, Roman Hájek, Miroslav Červinka, Emil Rudolf, Luděk Pour, Radovan Slezák, Ivan Špıčka and Jan Peychl and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and British Journal of Haematology.

In The Last Decade

Jakub Radocha

49 papers receiving 277 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jakub Radocha Czechia 10 151 124 114 40 37 57 287
Megan Kelly United States 6 126 0.8× 76 0.6× 159 1.4× 13 0.3× 125 3.4× 12 305
M Renoux France 8 146 1.0× 40 0.3× 52 0.5× 86 2.1× 26 0.7× 23 286
Stephen H. Leech United States 12 92 0.6× 29 0.2× 60 0.5× 25 0.6× 34 0.9× 29 326
Floor Heubel-Moenen Netherlands 7 114 0.8× 39 0.3× 86 0.8× 22 0.6× 15 0.4× 25 219
Maham Hayat United States 11 93 0.6× 92 0.7× 38 0.3× 29 0.7× 32 0.9× 56 292
Kristan Augustin United States 10 134 0.9× 96 0.8× 67 0.6× 35 0.9× 64 1.7× 20 310
Yiu Ming Yeung China 6 84 0.6× 36 0.3× 73 0.6× 32 0.8× 48 1.3× 16 291
Jie Peng China 12 45 0.3× 75 0.6× 101 0.9× 28 0.7× 39 1.1× 29 302
Alice Wolfromm France 6 92 0.6× 24 0.2× 60 0.5× 68 1.7× 38 1.0× 10 274
Aasiya Matin United States 5 42 0.3× 31 0.3× 62 0.5× 12 0.3× 22 0.6× 18 170

Countries citing papers authored by Jakub Radocha

Since Specialization
Citations

This map shows the geographic impact of Jakub Radocha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jakub Radocha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jakub Radocha more than expected).

Fields of papers citing papers by Jakub Radocha

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jakub Radocha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jakub Radocha. The network helps show where Jakub Radocha may publish in the future.

Co-authorship network of co-authors of Jakub Radocha

This figure shows the co-authorship network connecting the top 25 collaborators of Jakub Radocha. A scholar is included among the top collaborators of Jakub Radocha based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jakub Radocha. Jakub Radocha is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Žák, Pavel, Jakub Radocha, Benjamín Víšek, et al.. (2025). Population Pharmacokinetic Model‐Based Optimization of Linezolid Dosing in Hematooncological Patients With Suspected or Proven Gram‐Positive Sepsis. Clinical and Translational Science. 18(9). e70346–e70346.
2.
Minařík, Jiří, Luděk Pour, Tomáš Jelı́nek, et al.. (2025). Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group. BMC Cancer. 25(1). 651–651.
3.
4.
Špıčka, Ivan, Maximilian Merz, Jakub Radocha, et al.. (2023). P944: REAL-WORLD PATIENT CHARACTERISTICS AND SURVIVAL OUTCOMES OF LENALIDOMIDE REFRACTORY VS. LENALIDOMIDE EXPOSED RRMM PATIENTS IN THE HONEUR FEDERATED DATA NETWORK. HemaSphere. 7(S3). e258126d–e258126d. 2 indexed citations
5.
Štork, Martin, Ivan Špıčka, Jakub Radocha, et al.. (2023). Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis. Annals of Hematology. 102(6). 1501–1511. 6 indexed citations
6.
Pour, Luděk, Ivan Špıčka, Jakub Radocha, et al.. (2023). P1294: REAL-WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS. HemaSphere. 7(S3). e0151603–e0151603. 1 indexed citations
7.
Štork, Martin, Sabina Ševčı́ková, Tomáš Jelı́nek, et al.. (2022). Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas. Biomedicines. 10(10). 2535–2535. 2 indexed citations
8.
Maisnar, Vladimír, Luděk Pour, Ivan Špıčka, et al.. (2022). Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry Data. Clinical Lymphoma Myeloma & Leukemia. 23(2). 145–153. 4 indexed citations
9.
Šíma, Martin, Jana Maláková, Pavel Žák, et al.. (2022). Superiority of ceftazidime off‐label high‐dose regimen in PK/PD target attainment during treatment of extensively drug‐resistant Pseudomonas aeruginosa infections in cancer patients. British Journal of Clinical Pharmacology. 89(4). 1452–1461. 4 indexed citations
10.
Minařík, Jiří, Jakub Radocha, Alexandra Jungová, et al.. (2022). Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy. Cancers. 14(20). 5165–5165. 5 indexed citations
11.
Sandecká, Viera, Luděk Pour, Ivan Špıčka, et al.. (2022). Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data. Neoplasma. 69(6). 1474–1479. 2 indexed citations
12.
Smolej, Lukáš, et al.. (2021). Prognostic factors affecting the outcome after allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome. SHILAP Revista de lepidopterología. 16. 100274–100274.
13.
Slezák, Radovan, et al.. (2020). Oral Manifestations of Nutritional Deficiencies: Single Centre Analysis. SHILAP Revista de lepidopterología. 63(3). 95–100. 9 indexed citations
14.
15.
16.
Radocha, Jakub, et al.. (2017). Viridans group streptococci bloodstream infections in neutropenic adult patients with hematologic malignancy: Single center experience. Folia Microbiologica. 63(2). 141–146. 10 indexed citations
17.
Radocha, Jakub, et al.. (2016). Oral manifestation of sarcoidosis: A case report and review of the literature. Journal of Indian Society of Periodontology. 20(6). 627–627. 6 indexed citations
18.
Almáši, Martina, Sabina Ševčı́ková, Ondřej Slabý, et al.. (2011). Association Study of Selected Genetic Polymorphisms and Occurrence of Venous Thromboembolism in Patients With Multiple Myeloma Who Were Treated With Thalidomide. Clinical Lymphoma Myeloma & Leukemia. 11(5). 414–420. 11 indexed citations
19.
Maisnar, Vladimír, et al.. (2008). [Monoclonal gammopathies of undetermined significance].. PubMed. 21(4). 160–4. 1 indexed citations
20.
Maisnar, Vladimír, et al.. (2007). Monotherapy with low‐dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment. European Journal Of Haematology. 79(4). 305–309. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Megan Kelly Breakdown of academic impact, for papers by M Renoux Breakdown of academic impact, for papers by Stephen H. Leech Breakdown of academic impact, for papers by Floor Heubel-Moenen Breakdown of academic impact, for papers by Maham Hayat Breakdown of academic impact, for papers by Kristan Augustin Breakdown of academic impact, for papers by Yiu Ming Yeung Breakdown of academic impact, for papers by Jie Peng Breakdown of academic impact, for papers by Alice Wolfromm Breakdown of academic impact, for papers by Aasiya Matin
Rankless by CCL
2026